YBX1 and osteosarcoma: Class I HDACs, such as MS-275, can enhance the ROS levels in osteosarcoma, while inhibiting YB1-mediated antioxidant regulator NRF2 expression, thereby indirectly increasing ROS levels in tumor cells.